Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002
We would like to point out an error appearing in the article on topical cidofovir by Toro et al.1 In the "Solution" section, the first sentence reads, "Topical 3% cidofovir was compounded as follows: 15 g of cidofovir (75 mg/mL) was mixed with 22.5 g of a combination vehicle (Dermovan; Galderma Laboratory Inc, Fort Worth, Tex)."
Cidofovir (Vistide Injection; Gilead Sciences, Inc, Foster City, Calif) is supplied at a concentration of 75 mg/mL and packaged as 375 mg in a 5-mL single-unit glass vial. To add 15 g of cidofovir to the vehicle would require adding 200 mL of cidofovir solution. The resulting mixture would have a final concentration of 6.7%.
Goldblum OM, Zabawski EJ. Compounding of Topical Cidofovir. Arch Dermatol. 2002;138(2):267. doi:10.1001/archderm.138.2.266
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: